AI assistant
Pyxis Oncology, Inc. — Director's Dealing 2021
Oct 8, 2021
33976_dirs_2021-10-07_13d20ce9-f9e6-4be7-ad46-797214660511.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Pyxis Oncology, Inc. (PYXS)
CIK: 0001782223
Period of Report: 2021-10-07
Reporting Person: Herbst Ronald (N/A)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 90422 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to buy) | $5.34 | 2031-03-30 | Common Stock (297138) | Direct | |
| Stock Option (Right to buy) | $8.71 | 2031-09-14 | Common Stock (10304) | Direct |
Footnotes
F1: Includes 43,327 shares of restricted stock that are subject to vesting in 23 substantially-equal monthly installments beginning October 21, 2021, subject to the reporting person's continued employment through the applicable vesting date.
F2: These stock options vest in 48 substantially-equal monthly installments beginning September 21, 2019, subject to the reporting person's continued employment through the applicable vesting date.
F3: These stock options vest 25% on the first anniversary of the closing of the Issuer's initial public offering, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.